cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30747807.v1
title: Nonlinear relationship associations between a lipid composite index and asthma in middle-aged women: a cross-sectional study from NHANES 2007-2016

description: Background Asthma demonstrates pronounced sex-based disparities, with adult females exhibiting a disproportionately higher disease burden. Although aberrant lipid metabolic profiles have been mechanistically linked to asthma pathogenesis, the specific association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and asthma risk in women remains unclear. This study aims to investigate the relationship between NHHR and asthma risk in middle-aged women using a nationally representative U.S. population. Methods Data were obtained from the National Health and Nutrition Examination Survey (NHANES) 2007-2016. A variety of statistical methods, such as multivariate logistic regression, smoothed curve fitting, threshold effects, and subgroup analyses, were applied to explore the relationship between NHHR and asthma risk. Results A total of 7,337 participants aged 30–65 years were included, with an asthma prevalence of 16.82%. After full adjustment for demographic, socioeconomic, lifestyle, and clinical factors, higher NHHR levels were positively associated with asthma risk (OR = 1.26, 95% CI: 1.01, 1.58). Smooth curve fitting demonstrated a nonlinear relationship with a threshold inflection point at Log10(NHHR) = 0.07 (corresponding to NHHR ≈ 1.17). Above this threshold, asthma risk increased significantly (OR = 1.78, 95% CI: 1.24–2.54). Subgroup analyses indicated a significant interaction by education level, with stronger associations observed among women with lower educational attainment. Conclusions Elevated NHHR is independently and nonlinearly associated with asthma risk in middle-aged women. The findings suggest that dysregulated lipid metabolism may contribute to asthma susceptibility, highlighting NHHR as a potential biomarker for metabolic-inflammatory crosstalk and in women’s respiratory health.
DOI: 10.15482/usda.adc/31076404
title: Data from: Evaluation of a co-inoculation method for <i>Salmonella enterica</i> and <i>Enterococcus faecium</i> NRRL B-2354 on whole and broken almonds exposed to dry heat

description: Traditional laboratory-based pathogen-surrogate comparison studies often involve inoculating each organism onto separate samples, which can subsequently introduce variability due to differences in food microenvironments and processing conditions. Co-inoculating pathogens and surrogates onto the same sample minimizes this variability by subjecting both microorganisms to identical conditions. This study evaluated a co-inoculation method for<i> </i>comparing the thermal resistance of <i>Salmonella enterica</i> and <i>Enterococcus faecium</i> on whole and broken almonds exposed to 168 °C for up to 12 min. Selective media were validated for accurate differentiation and enumeration of co-inoculated wild-type or rifampin-resistant <i>Salmonella</i> and<i> </i><i>E. faecium</i> on almonds. The media reliably distinguished and quantified each organism, with no cross-recovery observed. Reductions in<i> </i><i>Salmonella</i> were not significantly different between wild-type and rifampin-resistant strains, nor between CHROMagar Salmonella and tryptic soy agar supplemented with rifampin at 50 μg/mL (<i>P</i> &gt; 0.05). <i>E. faecium</i> demonstrated similar or greater thermal resistance compared to co-inoculated <i>Salmonella</i>, supporting its use as a surrogate during dry heat treatment of almonds. While no significant difference in <i>Salmonella </i>reduction was observed between whole and broken almonds, greater reductions of <i>E. faecium</i> were observed on broken almonds, suggesting that almond structure may influence microbial thermal responses in a species-dependent manner. The findings support the utility of co-inoculation for laboratory-based pathogen-surrogate comparison studies.
DOI: 10.15482/usda.adc/31076404.v1
title: Data from: Evaluation of a co-inoculation method for <i>Salmonella enterica</i> and <i>Enterococcus faecium</i> NRRL B-2354 on whole and broken almonds exposed to dry heat

description: Traditional laboratory-based pathogen-surrogate comparison studies often involve inoculating each organism onto separate samples, which can subsequently introduce variability due to differences in food microenvironments and processing conditions. Co-inoculating pathogens and surrogates onto the same sample minimizes this variability by subjecting both microorganisms to identical conditions. This study evaluated a co-inoculation method for<i> </i>comparing the thermal resistance of <i>Salmonella enterica</i> and <i>Enterococcus faecium</i> on whole and broken almonds exposed to 168 °C for up to 12 min. Selective media were validated for accurate differentiation and enumeration of co-inoculated wild-type or rifampin-resistant <i>Salmonella</i> and<i> </i><i>E. faecium</i> on almonds. The media reliably distinguished and quantified each organism, with no cross-recovery observed. Reductions in<i> </i><i>Salmonella</i> were not significantly different between wild-type and rifampin-resistant strains, nor between CHROMagar Salmonella and tryptic soy agar supplemented with rifampin at 50 μg/mL (<i>P</i> &gt; 0.05). <i>E. faecium</i> demonstrated similar or greater thermal resistance compared to co-inoculated <i>Salmonella</i>, supporting its use as a surrogate during dry heat treatment of almonds. While no significant difference in <i>Salmonella </i>reduction was observed between whole and broken almonds, greater reductions of <i>E. faecium</i> were observed on broken almonds, suggesting that almond structure may influence microbial thermal responses in a species-dependent manner. The findings support the utility of co-inoculation for laboratory-based pathogen-surrogate comparison studies.
DOI: 10.15468/dl.rn244w
title: Occurrence Download

description: A dataset containing 277 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Mexico",
 "StateProvince is Nuevo Leon",
 "TaxonKey is Cactaceae"
 ]
}

 The dataset includes 277 records from 16 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0016253-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00010036
title: Development of statistical methodology considering placebo response in randomized controlled trials targeting Alzheimer's disease

description:      Alzheimer's disease (AD) is one of the causes of dementia, which is characterized by long-term decline in cognitive function. Currently, more than 55 million people worldwide are living with dementia, and AD is thought to be involved in 60-70% of cases. As more people live longer, more individuals are developing AD. We urgently need to find effective treatments. Clinical trials are commonly conducted to find effective treatments. These trials compare potential medicine with placebos, which are fake medicines with no real treatment. However, in trials testing potential treatments for AD, most medicine didn't work better than placebos.  
     One potential reason why these clinical trials have failed is the high placebo response, where groups that took a placebo (placebo groups) showed high improvement in cognitive function, making it hard to detect the true effects of the drugs being tested. 
Other disease areas like depression have extensively studied the placebo response. Research in this field suggests that the high placebo response caused many clinical trials for depression drugs to seem unsuccessful, even if the drugs were truly effective. Scientists are developing new statistical methods to account for the placebo response when analyzing the results of these trials. However, research examining the placebo response in clinical trials for AD has been limited. For AD trials as well, understanding the placebo response could greatly contribute to finding better treatments.
     In this study, we will use data from past AD clinical trials' placebo groups. Based on previous research, placebo high responders will be defined. Each patient's data will be examined to determine if they are placebo high responders. Using this information, the study will investigate the extent to which placebo response impacts results in clinical trials, and identify characteristics of patients prone to be placebo high responders. It will identify which types of AD patients are prone to be placebo high responders and develop new statistical methods to evaluate treatment efficacy while considering placebo response.
     If we can better identify placebo high responders and adjust for their influence, the risk of promising treatments failing in clinical trials due to the participation of placebo responders would decrease. This could make future AD drug trials more successful. Ultimately, this research could help provide effective treatments for Alzheimer's patients worldwide.
DOI: 10.25934/pr00009085
title: Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo

description: Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized by progressive decline in cognitive function and ability to perform activities of daily living, and ultimately can lead to death due to complications of the disease. AD is thought to be caused by an excess of A-Beta amyloid, a sticky protein in the brain that forms amyloid plaques. Treatments that slow the synthesis or deposition of A-Beta amyloid, or that increase clearance, might be expected to slow the progression of AD. LY2062430 (solanezumab) is a humanized anti-A Beta peptide immunoglobulin G-1 (IgG1) monoclonal antibody being developed for the treatment of AD. The primary hypothesis being tested is that LY2062430 will slow cognitive and functional decline in AD as compared with placebo. Each patient's participation will last approximately 19 months. Patients taking approved AD medications may participate in this study and continue taking these medications during the study.
DOI: 10.25934/pr00009086
title: Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo

description: Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized by progressive decline in cognitive function and ability to perform activities of daily living, and ultimately can lead to death due to complications of the disease. AD is thought to be caused by an excess of A-Beta amyloid, a sticky protein in the brain that forms amyloid plaques. Treatments that slow the synthesis or deposition of A-Beta amyloid, or that increase clearance, might be expected to slow the progression of AD. LY2062430 (solanezumab) is a humanized anti-A Beta peptide immunoglobulin G-1 (IgG1) monoclonal antibody being developed for the treatment of AD. The primary hypothesis being tested is that LY2062430 will slow cognitive and functional decline in AD as compared with placebo. Each patient's participation will last approximately 19 months. Patients taking approved AD medications may participate in this study and continue taking these medications during the study.
DOI: 10.25934/pr00009088
title: Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo

description: To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
DOI: 10.25934/00004434
title: Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo

description: Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta-amyloid (β-amyloid), a sticky protein in the brain that forms amyloid plaques. At autopsy, AD patients are required to have these amyloid plaques in the brain in order to have a definitive diagnosis of AD. Inhibiting the enzyme gamma-secretase (γ-secretase) lowers the production of β-amyloid. Semagacestat (LY450139) is a functional γ-secretase inhibitor and was shown to lower β-amyloid in blood and spinal fluid in humans tested thus far and in blood, spinal fluid, and brain in animals tested thus far. This study used several different tests to measure the effect of semagacestat on both β-amyloid and amyloid plaques for some participants. The build-up of amyloid plaques was measured by a brain scan that takes a picture of amyloid plaques in the brain. Other tests measured the overall function of the brain and brain size in some participants. In this trial, participants who initially received placebo (inactive sugar pill) were, at a certain point in the study, switched over to active drug, semagacestat. In other words, all participants could eventually receive active drug. Participation could last approximately 2 years. Participants taking approved AD medications were permitted to participate in this study and continue taking these medications during the study. All participants who completed this study had the option to continue receiving semagacestat by participating in an open-label study. Preliminary results from this study (H6L-MC-LFAN [LFAN]) and another similar study (H6L-MC-LFBC [LFBC; NCT00762411]) showed semagacestat did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. Study drug was stopped in all studies. Studies LFAN, LFBC, and open-label H6L-MC-LFBF (LFBF; NCT01035138) were amended to continue collecting safety data, including cognitive scores, for at least 7 months. The Clinical Trial Registry (CTR) will reflect results of analyses from the original LFAN protocol in addition to those from the amended LFAN protocol.
DOI: 10.25934/00004442
title: Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo

description: Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta amyloid (β-amyloid), a sticky protein in the brain that forms amyloid plaques. At autopsy, AD patients are required to have these amyloid plaques in the brain in order to have a definitive diagnosis of AD. Inhibiting the enzyme gamma-secretase (γ-secretase) lowers the production of β-amyloid. Semagacestat (LY450139) is a functional γ-secretase inhibitor and was shown to lower β-amyloid in blood and spinal fluid in humans tested thus far and in blood, spinal fluid and brain in animals tested thus far. This study used several different tests to measure the effect of semagacestat on both β-amyloid and amyloid plaques for some patients. The buildup of amyloid plaques was measured by a brain scan that takes a picture of amyloid plaques in the brain. Other tests measured the overall function of the brain and brain size in some patients. In this trial, patients who initially received placebo (inactive sugar pill) were, at a certain point in the study, switched over to active drug, semagacestat. In other words, all patients could eventually receive active drug. Each patient's participation could last approximately 2 years. Patients taking approved AD medications were permitted to participate in this study and continue taking these medications during the study. All patients who completed this study had the option to continue receiving semagacestat by participating in an open label study. Preliminary results from this study (LFBC) (and another similar study LFAN [NCT00594568]) showed semagacestat did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. Study drug was stopped in all studies. LFBC, LFAN and open label LFBF (NCT01035138) have been amended to continue collecting safety data, including cognitive scores, for at least seven months. The CT-Registry will reflect results of analyses from the original protocol in addition to those from the amended protocol.
DOI: 10.25345/c5qr4p45m
title: MassIVE MSV000100843 - Photoaffinity labeling of human coronavirus 229E-infected MRC5 cells
title: Proteomic analysis of photoaffinity tagged methyltransferase inhibitor treated human fibroblasts infected with human coronavirus 229E. MRC5 cells were mock-infected (saline buffer treatment only) or infected with human coronavirus 229E in the presence or absence of the photoaffinity tagged methyltransferase inhibitor (10 and 40 micromolar) for 48 hours. Cells were UV treated, scraped, and lysed in 0.5% sodium dodecyl sulfate. Click chemistry was performed on samples normalized for protein concentration and samples were resolved on 10 to 20% Tris Glycine gels. Affinity probed targeted proteins were enriched using streptavidin beads prior to being submitted for proteomics. Data was searched with MS-GF+ using PNNL's DMS Processing pipeline.
DOI: 10.15468/dl.x7m42p
title: Occurrence Download

description: A dataset containing 33 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Crenicichla cincta",
 "DecimalLatitude is not null",
 "DecimalLongitude is not null"
 ]
}

 The dataset includes 33 records from 11 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0016254-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.18635939
title: MODERN PROBLEMS OF IMMUNITY AND CHILDREN'S OBESITY

description: This scientific article provides a scientific and theoretical analysis of the increasing incidence of obesity among children and the role of malnutrition in this process. The study covers the daily diet of children, the composition of food products, the impact of high-calorie food consumption on the body, and the negative consequences of a sedentary lifestyle. The need to form a culture of healthy eating is substantiated based on scientific sources conducted in Uzbekistan.
DOI: 10.5281/zenodo.18635940
title: MODERN PROBLEMS OF IMMUNITY AND CHILDREN'S OBESITY

description: This scientific article provides a scientific and theoretical analysis of the increasing incidence of obesity among children and the role of malnutrition in this process. The study covers the daily diet of children, the composition of food products, the impact of high-calorie food consumption on the body, and the negative consequences of a sedentary lifestyle. The need to form a culture of healthy eating is substantiated based on scientific sources conducted in Uzbekistan.
DOI: 10.15468/dl.wp7zxt
title: Occurrence Download

description: A dataset containing 377155 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Digitalis purpurea"
 ]
}

 The dataset includes 377155 records from 1727 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0016191-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.3535/rdk-7r3-a59
title: Emoda submarginata (J. E. Gray, 1825)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/mx8-567-83l
title: Metaxia excelsa Faber & Moolenbeek, 1991

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/hkr-cvt-a2c
title: Hinea lineata (da Costa, 1778)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.15468/dl.jnd7xt
title: Occurrence Download

description: A dataset containing 1291690 records in GBIF matching the query:
SELECT
 gbifid,
 datasetkey,
 materialsampleid,
 catalognumber,
 othercatalognumbers,
 occurrenceid,
 materialentityid,
 ownerinstitutioncode,
 institutionid,
 institutioncode,
 scientificname,
 vernacularname,
 scientificnameid,
 taxonkey,
 preparations,
 license,
 modified,
 locality,
 county,
 municipality,
 verbatimlocality,
 island,
 v_verbatimcoordinates,
 v_verbatimlongitude,
 v_verbatimlatitude,
 continent,
 v_country,
 countrycode,
 islandgroup,
 stateprovince,
 waterbody,
 highergeography,
 locationid,
 decimallatitude,
 decimallongitude,
 footprintwkt,
 recordedby,
 recordedbyid,
 eventdate,
 "year",
 verbatimeventdate,
 fieldnumber,
 recordnumber,
 mediatype,
 v_associatedmedia,
 dwcaextension,
 "references",
 v_geodeticdatum,
 coordinateuncertaintyinmeters,
 coordinateprecision,
 footprintsrs,
 identifiedbyid
FROM
 occurrence
WHERE
 occurrence.basisofrecord = 'PRESERVED_SPECIMEN'
 AND occurrence.datasetkey = 'bf2a4bf0-5f31-11de-b67e-b8a03c50a862'
 AND occurrence.class IN ('Magnoliopsida', 'Liliopsida')
 AND (occurrence.materialsampleid IS NOT NULL OR occurrence.catalognumber IS NOT NULL OR occurrence.othercatalognumbers IS NOT NULL OR occurrence.occurrenceid IS NOT NULL OR occurrence.materialentityid IS NOT NULL)
 AND (occurrence.ownerinstitutioncode IS NOT NULL OR occurrence.institutionid IS NOT NULL OR occurrence.institutioncode IS NOT NULL)
 AND (occurrence.scientificname IS NOT NULL OR occurrence.vernacularname IS NOT NULL OR occurrence.scientificnameid IS NOT NULL OR occurrence.taxonkey IS NOT NULL)
 AND occurrence.preparations IS NOT NULL
 AND occurrence.license IS NOT NULL
 AND occurrence.modified IS NOT NULL

 The dataset's 1291690 records were derived from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0008761-250811113504898/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.3535/719-wn4-dcb
title: Epitonium Röding, 1798

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/n6c-3rt-9sl
title: Vermetidae Rafinesque, 1815

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.7910/dvn/zzqeu6
title: How Does Mass Prestige and brand competitiveness influence consumer happiness through brand repetitiveness: An experimental study
title: Consumer happiness

description: How Does Mass Prestige and brand competitiveness influence consumer happiness through brand repetitiveness: An experimental study
description: SmartPLS
DOI: 10.3535/75v-8kl-hm6
title: Trivirostra oryza (Lamarck, 1810)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/sg1-23m-9fp
title: Melampus coffea (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/6ey-jdx-xkt
title: Monetaria moneta (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/b8e-z9f-x59
title: Cyclophorus rafflesii (Broderip & G. B. Sowerby I, 1830)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/2bk-7hd-aym
title: Erronea caurica quinquefasciata (Röding, 1798)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.34740/kaggle/dsv/12771520
title: Trending Youtube Video Statistics (113 Countries)
DOI: 10.3535/66d-xbn-f6a
title: Schwartziella bryerea (Montagu, 1803)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/99g-l1l-e3t
title: Euspira fusca (Blainville, 1825)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/7by-c77-z9g
title: Alvania rudis (R. A. Philippi, 1844)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.